Followers | 17 |
Posts | 1755 |
Boards Moderated | 0 |
Alias Born | 11/13/2013 |
Wednesday, January 15, 2020 3:59:21 PM
THE HONORABLE MIRANDA M. DU, U.S. DISTRICT JUDGE
DEPUTY CLERK: PEGGIE VANNOZZI COURT REPORTER: KATHY FRENCH
COUNSEL FOR PLAINTIFFS: Megan Keane, Christopher Sipes, Michael
Kennedy, Jeffrey Ellikan, Alaina Whitt, Han
Park, Daniel Farnolly, Eric Sonnenschein
COUNSEL FOR DEFENDANT HIKMA: Charles Klein, Eimeric Reig-Plessis, W. West
Allen, Clair Fundakowski, Allison Heydorn
COUNSEL FOR DEFENDANT DRL: Constance Huttner, Michael Rounds, James
Barabas
IN COURT PROCEEDINGS: Bench trial, day 2
Proceedings begin at 8:33 AM. Also present for Amarin: Joseph Kennedy as corporate representative, Barbara Kurys as patent counsel and Litigation Support Technician
David Brooks. Also present for Defendants: Neema Kumar as corporate representative for Hikma, Andrew Allen and Deeph Jain as corporate representatives for DR and Litigation Support Technician Stephen Gros.
Ms. Keane advises that there is an error in Defendant’s demonstrative slides used in cross examination of Steve Ketchum. Mr. Sipes suggests that Defense counsel could prepare a chart citing the specific “DDX” numbers. The court will address the concern later in the day. The Court encourages counsel to meet and conferment o reach a resolution.
Matthew Budoff is sworn to testify. Mr. Kennedy examines the witness. Plaintiff’s exhibit 1186 is marked and admitted. Stipulated exhibit 940 is admitted.
Recess: 10:18 AM – 10:39 AM.
Direct examination of Steve Ketchum resumes. Plaintiff’s exhibit 1161 is marked and admitted. The witness is qualified as an expert in the areas of clinical treatment of lipidemia, including TG, and cardiology. Plaintiff’s exhibits 989 and 269 are marked and admitted.
Recess: 9:12 AM – 9:38 AM (to resolve a technical issue.)
Direct examination of Matthew Budoff resumes. Plaintiff’s exhibits 566, 1203, 1209, 288, 289, 277 and 285 are marked and admitted.
Recess: 10:55 AM – 11:21 AM.
Direct examination of Matthew Budoff resumes. Plaintiff’s exhibits 26, 25, 22, 30, and 31 are marked and admitted.
Recess: 12:24 PM – 1:04 PM
Ms. Klein conducts cross examination of Matthew Budoff. Defendant’s exhibits 1982, 1632, and 1578 are marked and admitted. . Defendant’s exhibit 1554 is marked.
Recess: 2:55 PM – 3:16 PM.
Cross examination of Matthew Budoff resumes. Defendant’s exhibits 203 and 2247 are marked and admitted. Mr. Kennedy conducts redirect examination. The witness is excused.
Mr. Sipes advises that Plaintiff closes their case.
Ms. Fundakowski presents Defendants’ Rule 52(c) motion. Mr. Sipes responds. The Court reserves its ruling.
Jonathan Scheinberg is sworn to testify. Mr. Reig examines the witness. Defendants’ exhibit 2226 is marked and admitted. The witness is qualified as an expert in cardiology. Defendant’s exhibits 1953, 1957, 2266,.1984 and 1679 are marked and admitted. Defendant’s exhibit 1960 is marked. The witness steps down.
The Court advises counsel that it will issue an oral ruling on Defendants’ Rule 52(c) motion. For the reasons the Court has placed on the record, Defendants’ Rule 52(c) motion is denied.
The Court has reviewed the 25 exhibits Defendants added to their exhibit list. The court encourages counsel to resolve the evidentiary issues. The Court will not exclude the late disclosed exhibits. Plaintiff’s oral motion to exclude the late disclosed exhibits is denied.
Counsel agree to file the chart referencing the exhibits, page numbers and “DDX” numbers Mr. Klein utilized in cross examination of Steve Ketchum in CM/ECF. The Courtroom Administrator will file the minutes of proceedings for January 13, 2020.
The bench trial is continued to January 15, 2020 at 8:30 AM.
Recess: 5:32 PM.
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM